|
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |
|
|
|
|||||||||
|
|||||||||||
|
J Am Coll Cardiol, 2001; 37:1001-1007 © 2001 by the American College of Cardiology Foundation |
* Duke Clinical Research Institute, Durham, North Carolina, USA
Cleveland Clinic Foundation, Cleveland, Ohio, USA
University of Alberta, Edmonton, Alberta, Canada
Hospital Clinic I, Barcelona, Spain
|| McMaster University, Hamilton, Ontario, Canada
¶ Ospedale Maggiore di Parma, Parma, Italy
Manuscript received July 10, 2000; revised manuscript received November 9, 2000, accepted December 13, 2000.
Reprint requests and correspondence: Dr. Maria Cecilia Bahit, Duke Clinical Research Institute, PO Box 17969, Durham, North Carolina 27715
bahit001{at}mc.duke.edu
OBJECTIVES
We sought to determine the incidence of and risk factors for thrombotic events early after discontinuing antithrombin therapy in patients with acute coronary syndromes.
BACKGROUND
Discontinuation of treatment with heparin and other thrombin inhibitors in patients with unstable coronary syndromes has related to clinical and biochemical evidence of early reactivation of thrombosis.
METHODS
We studied 8,943 of the 12,142 patients with acute coronary syndromes enrolled in the Global Use of Strategies To Open occluded arteries in acute coronary syndromes trial of hirudin versus heparin. We excluded patients who received no study drug, lacked timing data, died or had myocardial (re)infarction [(re)MI] during study-drug infusion, or began heparin treatment within 2 h after treatment with the study drug was stopped. We assessed the incidence and timing of (re)MI by type and timing of antithrombin treatment.
RESULTS
In all, 215 patients (2.4%) suffered (re)MI, 49 within 12 h of antithrombin therapy discontinuation and 166 between hour 12 and hospital discharge. The duration of infusion did not differ between the hirudin and heparin groups. The rate of early re(MI) after drug therapy discontinuation was significantly higher in patients given heparin versus hirudin (0.8% vs. 0.3%, p = 0.002). Patients with (re)MI had higher mortality at 30 days (23.6% vs. 2.4%, p = 0.001) and 1 year (35.2% vs. 6.7%, p = 0.001) compared with patients without (re)MI.
CONCLUSIONS
The incidence of (re)MI was clustered within 12 h of heparin therapy discontinuation, with the greatest risk within 4 h. There was no evidence of early reactivation of thrombotic events after hirudin. Patients who had (re)infarction had worse outcomes. Better understanding of the mechanism and possible prevention of recurrent thrombosis is needed.
| ||||||||||||||||||||||||||
This article has been cited by other articles:
|
|
 |
|
  M. Levi, M. Levy, M. D. Williams, I. Douglas, A. Artigas, M. Antonelli, D. Wyncoll, J. Janes, F. V. Booth, D. Wang, et al. Prophylactic Heparin in Patients with Severe Sepsis Treated with Drotrecogin Alfa (Activated) Am. J. Respir. Crit. Care Med., September 1, 2007; 176(5): 483 - 490. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. R. Bijsterveld, R. J. G. Peters, S. A. Murphy, P. J. L. M. Bernink, J. G. P. Tijssen, M. Cohen, and TIMI 11B/ESSENCE Study Groups Recurrent cardiac ischemic events early after discontinuation of short-term heparin treatment in acute coronary syndromes: Results from the thrombolysis in myocardial infarction (TIMI) 11B and efficacy and safety of subcutaneous enoxaparin in Non-Q-Wave coronary events (ESSENCE) studies J. Am. Coll. Cardiol., December 17, 2003; 42(12): 2083 - 2089. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Cohen, G. F. Gensini, F. Maritz, E. P. Gurfinkel, K. Huber, A. Timerman, M. Krzeminska-Pakula, N. Danchin, H. D. White, J. Santopinto, et al. The safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and tirofiban versus placebo in the treatment of acute ST-segment elevation myocardial infarction patients ineligible for reperfusion (TETAMI): A randomized trial J. Am. Coll. Cardiol., October 15, 2003; 42(8): 1348 - 1356. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. G. Goodman, D. Fitchett, P. W. Armstrong, M. Tan, A. Langer, and for the Integrilin and Enoxaparin Randomized Asses Randomized Evaluation of the Safety and Efficacy of Enoxaparin Versus Unfractionated Heparin in High-Risk Patients With Non-ST-Segment Elevation Acute Coronary Syndromes Receiving the Glycoprotein IIb/IIIa Inhibitor Eptifibatide Circulation, January 21, 2003; 107(2): 238 - 244. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. R. Bijsterveld, A. H. Moons, J. C. M. Meijers, J. G. P. Tijssen, H. R. Buller, M. Levi, and R. J. G. Peters Rebound thrombin generation after heparin therapy in unstable angina: A randomized comparison between unfractionated and low-molecular-weight heparin J. Am. Coll. Cardiol., March 6, 2002; 39(5): 811 - 817. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Lauer, P. L. Houghtaling, J. G. Peterson, C. B. Granger, D. L. Bhatt, S. K. Sapp, M. L. Simoons, R. A. Harrington, E. J. Topol, and A. M. Lincoff Attenuation of Rebound Ischemia After Discontinuation of Heparin Therapy by Glycoprotein IIb/IIIa Inhibition With Eptifibatide in Patients With Acute Coronary Syndromes: Observations From the Platelet IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Circulation, December 4, 2001; 104(23): 2772 - 2777. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. P. Hudson, C. B. Granger, E. J. Topol, K. S. Pieper, P. W. Armstrong, G. I. Barbash, A. D. Guerci, A. Vahanian, R. M. Califf, and E. M. Ohman Early Reinfarction After Fibrinolysis: Experience From the Global Utilization of Streptokinase and Tissue Plasminogen Activator (Alteplase) for Occluded Coronary Arteries (GUSTO I) and Global Use of Strategies To Open Occluded Coronary Arteries (GUSTO III) Trials Circulation, September 11, 2001; 104(11): 1229 - 1235. [Abstract] [Full Text] [PDF]
|
|
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |
